Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort.
dc.contributor.author | Urowitz, M B | |
dc.contributor.author | Gladman, D D | |
dc.contributor.author | Ibañez, D | |
dc.contributor.author | Fortin, P R | |
dc.contributor.author | Bae, S C | |
dc.contributor.author | Gordon, C | |
dc.contributor.author | Clarke, A | |
dc.contributor.author | Bernatsky, S | |
dc.contributor.author | Hanly, J G | |
dc.contributor.author | Isenberg, D | |
dc.contributor.author | Rahman, A | |
dc.contributor.author | Sanchez-Guerrero, J | |
dc.contributor.author | Wallace, D J | |
dc.contributor.author | Ginzler, E | |
dc.contributor.author | Alarcón, G S | |
dc.contributor.author | Merrill, J T | |
dc.contributor.author | Bruce, I N | |
dc.contributor.author | Sturfelt, G | |
dc.contributor.author | Nived, O | |
dc.contributor.author | Steinsson, K | |
dc.contributor.author | Khamashta, M | |
dc.contributor.author | Petri, M | |
dc.contributor.author | Manzi, S | |
dc.contributor.author | Ramsey-Goldman, R | |
dc.contributor.author | Dooley, M A | |
dc.contributor.author | Van Vollenhoven, R F | |
dc.contributor.author | Ramos, M | |
dc.contributor.author | Stoll, T | |
dc.contributor.author | Zoma, A | |
dc.contributor.author | Kalunian, K | |
dc.contributor.author | Aranow, C | |
dc.date.accessioned | 2023-02-06T19:59:06Z | |
dc.date.available | 2023-02-06T19:59:06Z | |
dc.identifier.citation | Urowitz MB, Gladman DD, Ibañez D, Fortin PR, Bae SC, Gordon C, Clarke A, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Sanchez-Guerrero J, Wallace DJ, Ginzler E, Alarcón GS, Merrill JT, Bruce IN, Sturfelt G, Nived O, Steinsson K, Khamashta M, Petri M, Manzi S, Ramsey-Goldman R, Dooley MA, van Vollenhoven RF, Ramos M, Stoll T, Zoma A, Kalunian K, Aranow C. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2012 Jan;64(1):132-7. doi: 10.1002/acr.20648. PMID: 21954226. | en_US |
dc.identifier.eissn | 2151-4658 | |
dc.identifier.doi | 10.1002/acr.20648 | |
dc.identifier.pmid | 21954226 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12648/8251 | |
dc.description.abstract | We describe disease activity, damage, and the accrual of key autoantibodies in an inception systemic lupus erythematosus (SLE) cohort. | |
dc.description.abstract | The Systemic Lupus International Collaborating Clinics (SLICC) International Research Network, comprising 27 centers from 11 countries, has followed an inception cohort of SLE patients yearly according to a standardized protocol. Of these patients, 298 were followed for a minimum of 5 years and constitute the study population. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K) and damage was assessed using the SLICC/American College of Rheumatology Damage Index (SDI). Antinuclear antibody (ANA), anti-DNA, and anticardiolipin antibody (aCL) levels and lupus anticoagulant were assessed yearly. Descriptive statistics were generated and repeated-measures general linear models were used to evaluate SLEDAI-2K and SDI over time between whites and nonwhites. | |
dc.description.abstract | Of the 298 patients, 87% were women, 55% were white, 12% were African American, 14% were Asian, 16% were Hispanic, and 2% were categorized as "other." At enrollment, the mean age was 35.3 years, the mean SLEDAI-2K score was 5.9, and the mean disease duration was 5.5 months. Mean SLEDAI-2K scores decreased in the first year and then remained low. SLEDAI-2K scores were significantly lower at each year in whites compared to nonwhites. Mean SDI scores increased progressively over 5 years; there was no significant difference between whites and nonwhites. As expected, ANA positivity was high and anti-DNA positivity was relatively low at enrollment, and both increased over 5 years. Although lupus anticoagulant increased slightly over 5 years, aCL positivity did not. | |
dc.description.abstract | Disease activity in newly diagnosed patients decreases over their first 5 years, while damage increases. Antibody positivity ran variable courses over this period. | |
dc.language.iso | en | en_US |
dc.relation.url | https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.20648 | en_US |
dc.rights | Copyright © 2012 by the American College of Rheumatology. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. | en_US |
dc.type | Article/Review | en_US |
dc.source.journaltitle | Arthritis care & research | en_US |
dc.source.volume | 64 | |
dc.source.issue | 1 | |
dc.source.beginpage | 132 | |
dc.source.endpage | 7 | |
dc.source.country | Canada | |
dc.source.country | United States | |
dc.description.version | VoR | en_US |
refterms.dateFOA | 2023-02-06T19:59:06Z | |
html.description.abstract | We describe disease activity, damage, and the accrual of key autoantibodies in an inception systemic lupus erythematosus (SLE) cohort. | |
html.description.abstract | The Systemic Lupus International Collaborating Clinics (SLICC) International Research Network, comprising 27 centers from 11 countries, has followed an inception cohort of SLE patients yearly according to a standardized protocol. Of these patients, 298 were followed for a minimum of 5 years and constitute the study population. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K) and damage was assessed using the SLICC/American College of Rheumatology Damage Index (SDI). Antinuclear antibody (ANA), anti-DNA, and anticardiolipin antibody (aCL) levels and lupus anticoagulant were assessed yearly. Descriptive statistics were generated and repeated-measures general linear models were used to evaluate SLEDAI-2K and SDI over time between whites and nonwhites. | |
html.description.abstract | Of the 298 patients, 87% were women, 55% were white, 12% were African American, 14% were Asian, 16% were Hispanic, and 2% were categorized as "other." At enrollment, the mean age was 35.3 years, the mean SLEDAI-2K score was 5.9, and the mean disease duration was 5.5 months. Mean SLEDAI-2K scores decreased in the first year and then remained low. SLEDAI-2K scores were significantly lower at each year in whites compared to nonwhites. Mean SDI scores increased progressively over 5 years; there was no significant difference between whites and nonwhites. As expected, ANA positivity was high and anti-DNA positivity was relatively low at enrollment, and both increased over 5 years. Although lupus anticoagulant increased slightly over 5 years, aCL positivity did not. | |
html.description.abstract | Disease activity in newly diagnosed patients decreases over their first 5 years, while damage increases. Antibody positivity ran variable courses over this period. | |
dc.description.institution | SUNY Downstate | en_US |
dc.description.department | Rheumatology | en_US |
dc.description.degreelevel | N/A | en_US |
dc.identifier.journal | Arthritis care & research |